Subscribe by Email

About the Blog

The Active Ingredient features expert insights and commentary from leaders of ZS Associates' global pharmaceuticals practice.

Search by Topic

see all

Will Artificial Intelligence Usher in the Age of Industrial Medicine?

Posted by Paul Darling on Tue, Jan 22, 2019

This blog post is the final entry in a series on ZS’s 2018 AI in Healthcare study.

The U.S. healthcare system is expensive and wasteful, and is one of the least efficient in the world. More than half of doctors are burned out, and medical errors are the third leading cause of death. And if the healthcare experience doesn’t kill patients, it most definitely frustrates them: Patients in U.S. metropolitan areas reportedly wait an average of 24 days for a doctor’s appointment—up 30% since 2014.

Read More

Topics: Paul Darling, artificial intelligence, healthcare delivery, AI in Healthcare study, industrial medicine, data and interoperability, standardization of care, traditional medicine

The Death of Dashboards, and the Promise of Personalized Analytics

Posted by ZS Editors on Mon, Jan 07, 2019

Multiple factors are colliding to encourage the need for personalized analytics. The ever-expanding explosion of data is forcing companies to consider more nimble, automated solutions that simplify the user experience. The need for competitive advantage in a crowded marketplace is inspiring companies to arm reps with sales tools that give them an edge. Reps are increasingly expecting the kind of user experience that they get from consumer applications. The list goes on.

Personalization conjures a future where reps are no longer bombarded with information and expected to draw their own insights. In this future, AI-driven insights come to them as alerts on their mobile devices, personalized to their needs and customers, and delivered at the best possible time. 

But this is pharma. Surely the spreadsheets and dashboards will persist, right?

Read More

Topics: artificial intelligence, analytics disruption, commercial analytics, artificial intelligence & pharma, cutting-edge analytics, advanced analytics, personalized analytics, analytics maturity, data and insights

Making the Case for a New Analytics Consumption Model

Posted by ZS Editors on Thu, Nov 29, 2018

Industries like retail and technology are transitioning to an AI-driven, personalized approach to surfacing insights to end users, and they’re reaping the benefits. Life sciences companies have the same opportunity to capitalize on the runaway growth in data and rethink the way that analytics are consumed.  

ZS recently partnered with IDC to study how commercial life sciences teams are currently consuming data, and to determine their data and analytics pain points. The study revealed that sales and marketing professionals in life sciences want

Read More

Topics: Analytics, artificial intelligence, AI, data and analytics, analytics disruption, commercial analytics, artificial intelligence & pharma, cutting-edge analytics, advanced analytics, personalized analytics, analytics maturity, pharma commercial model

If AI Is the Engine and Patient Data Is its Fuel, Then Who’s in the Driver’s Seat?

Posted by Paul Darling on Wed, Oct 31, 2018

Pratap Khedkar co-wrote this blog post, the third in a series on ZS’s 2018 AI in Healthcare study, with Paul Darling.

Each time you visit the doctor, it’s the same scenario: You rattle off a bunch of information like medical history, lifestyle behaviors and choices, and current complaints, while she pounds away at a keyboard. You might have access to a portion of your medical record through a web-based patient portal, but otherwise that content is under the provider’s lock and key (unless you’re a New Hampshire resident). Don’t you wonder what your full electronic health record holds? Stakeholders throughout the healthcare ecosystem do, too.

Read More

Topics: Pratap Khedkar, Paul Darling, artificial intelligence, healthcare model, patient data, AI in Healthcare study, interoperability, digital connected health

The CVS/Aetna Merger Got the Greenlight, but Pharma Is Stuck at an Imaginary Red

Posted by Paul Darling on Mon, Oct 15, 2018

CVS Health and Aetna. Cigna and Express Scripts. Amazon, Berkshire Hathaway and JPMorgan Chase. Each one of these deals is evidence that corporate America will continue to march into the medical arena, uniting once-distinct healthcare enterprises under one roof. While the long-held divisions between U.S. healthcare stakeholders may be getting hazy, the aim is clear: to deliver convenient, high-quality care to consumers at a lower cost.

Read More

Topics: vertical integration, Paul Darling, artificial intelligence, real-world evidence, digital health tools, pharma business model, health and wellness

Subscribe to The Active Ingredient
SUBSCRIBE

Get 'THE ACTIVE INGREDIENT' Updates

Subscribe to receive email notifications whenever new blog posts are published.

×